This Article Full Text (PDF) Other Versions of this Article: CVI.00044-08v1 15/8/1282    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Quelhas, D. Articles by Dobaño, C. PubMed PubMed Citation Articles by Quelhas, D. Articles by Dobaño, C.

 Previous Article  |  Next Article 

Clin. Vaccine Immunol. doi:10.1128/CVI.00044-08
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Impact of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine on Antibody Responses to Erythrocytic Stage Antigens in Mozambican Infants

Centro de Investigação em Saúde da Manhiça (CISM), Manhiça, and Instituto Nacional de Saude, and Direcção Nacional de Saúde, Ministerio da Saúde, Maputo, Mozambique; Barcelona Centre for International Health Research (CRESIB), Hospital Clínic/IDIBAPS, Universitat de Barcelona, Spain; International Centre for Genetic Engineering and Biotechnology, New Delhi, India

^* To whom correspondence should be addressed. Email: cdobano{at}clinic.ub.es.

	Abstract

We evaluated the impact of Intermittent Preventive Treatment in infants (IPTi) with sulfadoxine-pyrimethamine (SP), given at ages 3, 4, and 9 months through the Expanded Program on Immunization, on the development of antibody responses to Plasmodium falciparum in Mozambique. IgM and IgG subclass antibodies specific to whole asexual parasites and to recombinant MSP-1₁₉, AMA-1 and EBA-175 were measured at ages 5, 9, 12 and 24 months in 302 children by immunofluorescence antibody test and by ELISA. Antibody responses did not significantly differ between children receiving IPTi with SP or placebo at any time point measured, with the exception of IgG and IgG1 to AMA-1 and/or MSP-1₁₉, which were significantly higher in the SP than in the placebo group at ages 5, 9 and/or 24 months. IPTi with SP given through the EPI reduces the frequency of malarial illness while allowing the development of naturally-acquired antibody responses to P. falciparum antigens.